Standard
Interleukin-1 antagonism in type 1 diabetes of recent onset : two multicentre, randomised, double-blind, placebo-controlled trials. / Moran, Antoinette; Bundy, Brian; Becker, Dorothy J; DiMeglio, Linda A; Gitelman, Stephen E; Goland, Robin; Greenbaum, Carla J; Herold, Kevan C; Marks, Jennifer B; Raskin, Philip; Sanda, Srinath; Schatz, Desmond; Wherrett, Diane K; Wilson, Darrell M; Krischer, Jeffrey P; Skyler, Jay S; Pickersgill, Linda; de Koning, Eelco; Ziegler, Anette-G; Böehm, Bernhard; Badenhoop, Klaus; Schloot, Nanette; Bak, Jens Friis; Pozzilli, Paolo; Mauricio, Didac; Donath, Marc Y; Castaño, Luis; Wägner, Ana; Lervang, Hans Henrik; Perrild, Hans; Mandrup-Poulsen, Thomas; Type 1 Diabetes TrialNet Canakinumab Study Group.
In:
Lancet, Vol. 381, No. 9881, 01.06.2013, p. 1905-15.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Moran, A, Bundy, B, Becker, DJ, DiMeglio, LA, Gitelman, SE, Goland, R, Greenbaum, CJ, Herold, KC, Marks, JB, Raskin, P, Sanda, S, Schatz, D, Wherrett, DK, Wilson, DM, Krischer, JP, Skyler, JS, Pickersgill, L, de Koning, E, Ziegler, A-G, Böehm, B, Badenhoop, K, Schloot, N, Bak, JF, Pozzilli, P, Mauricio, D, Donath, MY, Castaño, L, Wägner, A, Lervang, HH
, Perrild, H, Mandrup-Poulsen, T & Type 1 Diabetes TrialNet Canakinumab Study Group 2013, '
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials',
Lancet, vol. 381, no. 9881, pp. 1905-15.
https://doi.org/10.1016/S0140-6736(13)60023-9APA
Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., Sanda, S., Schatz, D., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S., Pickersgill, L., de Koning, E., Ziegler, A-G., ... Type 1 Diabetes TrialNet Canakinumab Study Group (2013).
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Lancet,
381(9881), 1905-15.
https://doi.org/10.1016/S0140-6736(13)60023-9Vancouver
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al.
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Lancet. 2013 Jun 1;381(9881):1905-15.
https://doi.org/10.1016/S0140-6736(13)60023-9Author
Moran, Antoinette ; Bundy, Brian ; Becker, Dorothy J ; DiMeglio, Linda A ; Gitelman, Stephen E ; Goland, Robin ; Greenbaum, Carla J ; Herold, Kevan C ; Marks, Jennifer B ; Raskin, Philip ; Sanda, Srinath ; Schatz, Desmond ; Wherrett, Diane K ; Wilson, Darrell M ; Krischer, Jeffrey P ; Skyler, Jay S ; Pickersgill, Linda ; de Koning, Eelco ; Ziegler, Anette-G ; Böehm, Bernhard ; Badenhoop, Klaus ; Schloot, Nanette ; Bak, Jens Friis ; Pozzilli, Paolo ; Mauricio, Didac ; Donath, Marc Y ; Castaño, Luis ; Wägner, Ana ; Lervang, Hans Henrik ; Perrild, Hans ; Mandrup-Poulsen, Thomas ; Type 1 Diabetes TrialNet Canakinumab Study Group. / Interleukin-1 antagonism in type 1 diabetes of recent onset : two multicentre, randomised, double-blind, placebo-controlled trials. In: Lancet. 2013 ; Vol. 381, No. 9881. pp. 1905-15.
Bibtex
@article{48e159d475264aaab6b9be91062dcd22,
title = "Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials",
abstract = "Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.",
keywords = "Adolescent, Adult, Analysis of Variance, Antibodies, Monoclonal, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Immunologic Factors, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Interleukin-1, Male, Treatment Outcome, Young Adult",
author = "Antoinette Moran and Brian Bundy and Becker, {Dorothy J} and DiMeglio, {Linda A} and Gitelman, {Stephen E} and Robin Goland and Greenbaum, {Carla J} and Herold, {Kevan C} and Marks, {Jennifer B} and Philip Raskin and Srinath Sanda and Desmond Schatz and Wherrett, {Diane K} and Wilson, {Darrell M} and Krischer, {Jeffrey P} and Skyler, {Jay S} and Linda Pickersgill and {de Koning}, Eelco and Anette-G Ziegler and Bernhard B{\"o}ehm and Klaus Badenhoop and Nanette Schloot and Bak, {Jens Friis} and Paolo Pozzilli and Didac Mauricio and Donath, {Marc Y} and Luis Casta{\~n}o and Ana W{\"a}gner and Lervang, {Hans Henrik} and Hans Perrild and Thomas Mandrup-Poulsen and {Type 1 Diabetes TrialNet Canakinumab Study Group}",
note = "Copyright {\textcopyright} 2013 Elsevier Ltd. All rights reserved.",
year = "2013",
month = jun,
day = "1",
doi = "10.1016/S0140-6736(13)60023-9",
language = "English",
volume = "381",
pages = "1905--15",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9881",
}
RIS
TY - JOUR
T1 - Interleukin-1 antagonism in type 1 diabetes of recent onset
T2 - two multicentre, randomised, double-blind, placebo-controlled trials
AU - Moran, Antoinette
AU - Bundy, Brian
AU - Becker, Dorothy J
AU - DiMeglio, Linda A
AU - Gitelman, Stephen E
AU - Goland, Robin
AU - Greenbaum, Carla J
AU - Herold, Kevan C
AU - Marks, Jennifer B
AU - Raskin, Philip
AU - Sanda, Srinath
AU - Schatz, Desmond
AU - Wherrett, Diane K
AU - Wilson, Darrell M
AU - Krischer, Jeffrey P
AU - Skyler, Jay S
AU - Pickersgill, Linda
AU - de Koning, Eelco
AU - Ziegler, Anette-G
AU - Böehm, Bernhard
AU - Badenhoop, Klaus
AU - Schloot, Nanette
AU - Bak, Jens Friis
AU - Pozzilli, Paolo
AU - Mauricio, Didac
AU - Donath, Marc Y
AU - Castaño, Luis
AU - Wägner, Ana
AU - Lervang, Hans Henrik
AU - Perrild, Hans
AU - Mandrup-Poulsen, Thomas
AU - Type 1 Diabetes TrialNet Canakinumab Study Group
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
AB - Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
KW - Adolescent
KW - Adult
KW - Analysis of Variance
KW - Antibodies, Monoclonal
KW - C-Peptide
KW - Child
KW - Diabetes Mellitus, Type 1
KW - Double-Blind Method
KW - Female
KW - Humans
KW - Hypoglycemic Agents
KW - Immunologic Factors
KW - Insulin-Secreting Cells
KW - Interleukin 1 Receptor Antagonist Protein
KW - Interleukin-1
KW - Male
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1016/S0140-6736(13)60023-9
DO - 10.1016/S0140-6736(13)60023-9
M3 - Journal article
C2 - 23562090
VL - 381
SP - 1905
EP - 1915
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9881
ER -
